A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer

Authors :: Abramson V
Oliveira M
Cervantes A
Wildiers H
Patel M
Bauer T
Bedard P
Becerra C
Richey S
Wei M
Reyner E
Bond J
Cui N
Wilson T
Moore H
Saura C
Krop I
Source :: BREAST CANCER RESEARCH AND TREATMENT, r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA, instname
Publication Year :: 2019
Publisher :: SPRINGER, 2019.

ISSN :: 01676806
Database :: OpenAIRE
Journal :: BREAST CANCER RESEARCH AND TREATMENT, r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA, instname
Accession number :: edsair.RECOLECTA.....e1ef52eb712a0bc75c21f04457f43565

Tools